Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109-5946, USA.
Semin Oncol. 2013 Jun;40(3):337-46. doi: 10.1053/j.seminoncol.2013.04.007.
Over the past 7 decades androgen-deprivation therapy (ADT) has been the cornerstone of treatment for metastatic non-castrate prostate cancer (NCPC); however, the mechanisms to achieve this goal have evolved over time to include not only bilateral orchiectomy and estrogens, but also gonadotropin-releasing hormone (GnRH) agonists, antagonists, and the inclusion of androgen receptor (AR) blockade. Despite treatment with ADT, most men will progress to castrate-resistant prostate cancer (CRPC). Over the last decade many new treatment options for CRPC have emerged. These new treatments also could have a meaningful role earlier in NCPC. In this review, we outline the biologic drivers of NCPC, review current standard therapy available for NCPC, and discuss the evolving role of new therapeutics in metastatic disease.
在过去的 70 年中，雄激素剥夺疗法（ADT）一直是治疗转移性去势抵抗性前列腺癌（NCPC）的基石；然而，实现这一目标的机制随着时间的推移而发展，不仅包括双侧睾丸切除术和雌激素，还包括促性腺激素释放激素（GnRH）激动剂、拮抗剂，以及雄激素受体（AR）阻断。尽管进行了 ADT 治疗，大多数男性仍会进展为去势抵抗性前列腺癌（CRPC）。在过去的十年中，出现了许多新的 CRPC 治疗选择。这些新的治疗方法在 NCPC 中也可能更早地发挥重要作用。在这篇综述中，我们概述了 NCPC 的生物学驱动因素，回顾了目前 NCPC 可用的标准治疗方法，并讨论了新疗法在转移性疾病中的作用不断发展。
